Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG) ANNALS OF ONCOLOGY Dabaja, B. S., Zelenetz, A. D., Ng, A. K., Tsang, R. W., Qi, S., Allen, P. K., Hodgson, D., Ricardi, U., Hoppe, R. T., Advani, R., Mauch, P. M., Constine, L. S., Specht, L., Li, Y., Terezakis, S. A., Wirth, A., Reinartz, G., Eich, H. T., Aleman, B. P., Barr, P., Yahalom, J. 2017; 28 (9): 2185–90


Mantle cell lymphoma (MCL) rarely presents as early-stage disease, but clinical observations suggest that patients who present with early-stage disease may have better outcomes than those with advanced-stage disease.In this 13-institution study, we examined outcomes among 179 patients with early-stage (stage I or II) MCL in an attempt to identify prognostic factors that influence treatment selection and outcome. Variables examined included clinical characteristics, treatment modality, response to therapy, sites of failure, and survival.Patients were predominantly male (78%) with head and neck being the most common presenting sites (75%). Most failures occurred outside the original disease site (79%). Although the administration of radiation therapy, either alone or with chemotherapy, reduced the risk of local failure, it did not translate into an improved freedom from progression or overall survival (OS). The treatment outcomes were independent of treatment modality. The 10-year OS for patients treated with chemotherapy alone, chemo-radiation therapy and radiation therapy alone were 69%, 62%, and 74% (P?=?0.79), and the 10-year freedom from progression were 46%, 43%, and 31% (P?=?0.64), respectively.Given the excellent OS rates regardless of initial therapy in patients with early-stage MCL, de-intensified therapy to limit treatment-related toxicity is a reasonable approach.

View details for PubMedID 28911068